Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676311 · ClinicalTrials.gov registry record · Phase 2
Effects of Huperzine A in Treatment of Moderate to Severe TBI
A Phase 2 study, sponsored by Spaulding Rehabilitation Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01676311 is a Phase 2 study that was terminated before completion, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 14 participants.
The verdict
NCT01676311, a Phase 2 study, was terminated before completion, sponsored by Spaulding Rehabilitation Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after TBI. Additionally, we aim to determine whether use of Huperzine A in these patients can change brain activity (as indexed by EEG and Transcranial Magnetic Stimulation - TMS), and reduce prevalence/frequency of post-traumatic seizures. We also aim to evaluate the safety of Huperzine A in this population as compared with placebo.
Interventions
- DRUG Placebo
- DRUG Huperzine A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-12 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676311
The ClinicalTrials.gov registry entry for NCT01676311 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spaulding Rehabilitation Hospital, which has 101 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01676311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676311 about?
NCT01676311 is a clinical study titled "Effects of Huperzine A in Treatment of Moderate to Severe TBI". We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after TBI. Additionally, we aim to determine whether use of Huperzine A in the...
What is the current status of trial NCT01676311?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2013-12. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01676311?
The interventions under investigation include: Placebo (DRUG), Huperzine A (DRUG).
Who is sponsoring clinical trial NCT01676311?
This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.